Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$54.3 million.

  • Rhythm Pharmaceuticals' Net Income towards Common Stockholders fell 20.70% to -$54.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.7 million, marking a year-over-year increase of 24.40%. This contributed to the annual value of -$264.6 million for FY2024, which is 43.26% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$54.3 million for Q3 2025, which was down 13.13% from -$48.0 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $43.8 million in Q1 2021 and a low of -$141.4 million during Q1 2024.
  • For the 3-year period, Rhythm Pharmaceuticals' Net Income towards Common Stockholders averaged around -$55.3 million, with its median value being -$48.0 million (2025).
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Net Income towards Common Stockholders surged by 228.06% in 2021, and later tumbled by 220.07% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$50.9 million in 2021, then increased by 16.44% to -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then decreased by 7.20% to -$44.6 million in 2024, then fell by 20.70% to -$54.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$54.3 million for Q3 2025, versus -$48.0 million for Q2 2025 and -$50.8 million for Q1 2025.